Showing 2801-2810 of 19323 results for "".
Clinical Exchanges®: Optimizing Management of Nontuberculous Mycobacteria Lung Disease
https://reachmd.com/programs/cme/clinical-exchanges-optimizing-management-of-nontuberculous-mycobacteria-lung-disease/11060/Explore the initial and ongoing management of nontuberculous mycobacteria lung disease through the use of shared decision making.How Epidermolysis Bullosa Treatments Went from Blisters to Breakthroughs
https://reachmd.com/topics/rare-disease/how-epidermolysis-bullosa-treatments-went-from-blisters-to-breakthroughs/54391/Current FDA-approved therapies oleogel-S10, beremagene geperpavec, and prademagene zamikeracel represent major therapeutic breakthroughs for the treatment of epidermolysis bullosa (EB). Earlier systemic intervention, improved nutrition, and proactive management of complications have extended survivAnti-Fibrotic ADCs Show Promise in Muscle Preservation for DMD
https://reachmd.com/programs/neurofrontiers/anti-fibrotic-adcs-show-promise-in-muscle-preservation-for-dmd/35684/Based on a recent preclinical study published in iScience, a novel antibody-drug conjugate approach reduces fibrosis and improves muscle function in a Duchenne muscular dystrophy (DMD) mouse model, highlighting its potential for early intervention therapies. Read more about the findings and how theyRedefining Risk in Endometrial Cancer: Recurrence Prediction with Machine Learning
https://reachmd.com/programs/project-oncology/redefining-risk-in-endometrial-cancer-recurrence-prediction-with-machine-learning/35508/A new study published in JCO Precision Oncology introduces a novel machine learning approach that could improve recurrence prediction in endometrial cancer. Though external validation remains a challenge, the results highlight a promising step towards personalized and proactive care for these pTargeting NETs: A New Frontier in COPD Treatment
https://reachmd.com/programs/clinicians-roundtable/targeting-nets-a-new-frontier-in-copd-treatment/26396/Here’s how targeting neutrophil extracellular traps can lead to reduced COPD side effects and the development of improved treatments.Staging the Benefit: Tafamidis Outcomes in ATTR-CM Depend on Timing
https://reachmd.com/programs/heart-matters/staging-the-benefit-tafamidis-outcomes-in-attr-cm-depend-on-timing/36137/Relapse Management in Multiple Sclerosis: Corticosteroids Remain the Linchpin of Therapies
https://reachmd.com/diseases-diagnoses/ms-immune-disorders/relapse-management-in-multiple-sclerosis-corticosteroids-remain-the-linchpin-of-therapies/32084/Several modalities are available for the treatment of multiple sclerosis relapse, including corticosteroids, intravenous immunoglobulins, and therapeutic apheresis.New Contact Lens Technology for Patients With Presbyopia, Dry Eye Disease, and Ocular Surface Disease
https://reachmd.com/empower-business-specialty-care-optometric-series/march-april-2026-supplement/new-contact-lens-technology-for-patients-with-presbyopia-dry-eye-disease-and-ocular-surface-disease/56897/A practical guide for new contact lens patients.Investigating Gene Therapy for DMD: The Role of Caregiver-Reporter Scales
https://reachmd.com/programs/neurofrontiers/investigating-gene-therapy-for-dmd-the-role-of-caregiver-reporter-scales/32359/Hear how researchers can use caregiver-reported scales to analyze gene therapy outcomes in Duchenne muscular dystrophy patients.Improving Risk Stratification in Lupus Nephritis: The Role of Urinary Biomarkers
https://reachmd.com/programs/living-rheum/improving-risk-stratification-in-lupus-nephritis-the-role-of-urinary-biomarkers/32798/